Furthermore, VDAC3 expression is upregulated in human malignant tumors, such as melanoma and thyroid tumors; VDAC3 is the binding site of the anticancer drug erastin, and overexpression of VDAC3 can increase sensitivity to erastin 8, 20-22. This evidence concerns the gene VDAC3 and thyroid tumor.